Specific active immunization with dengue type 2 virus (DV)-induced cytokine, cytotoxic factor (CF), prevents CF-mediated pathology in mice. The present study was undertaken to determine the optimum dose of CF and the effect of different adjuvants on the immune response as assessed by the study of anti-CF antibody titre by ELISA and protection against increase in capillary permeability to challenging dose of 3 Ag CF. The maximum protection of 94 4% against increase in capillary permeability was observed at week 4 after immunization with 5 Ag dose of CF mixed with Freund's incomplete adjuvant (FIA), which gradually decreased to 21 ± 10% on week 24. With a dose of 10 ig the protection obtained was 79 ± 5%, but persisted for a longer time at a higher level. The response was poor with 1 tg dose of CF. The mean anti-CF antibody titres gradually decreased after reaching the peak at week 4 after immunization. Mice immunized with different adjuvants emulsified with 5 pg CF were challenged at different intervals with 3 Aig CF. Maximum protection observed with CF + tetanus toxoid (TT) and 84/246 was about 93 ± 2% and 97 ± 2%, while that with alhydrogel was 33 12% and with bacille Calmette-Guerin (BCG) was 67 ± 4%. At week 24 after immunization, however, the best response was obtained with 10 ,ug of adjuvant 84/246. Intracerebral challenge with 10 or 100 LD50 dose of dengue type 2 virus showed significantly prolonged mean survival time and delayed onset of signs of sickness in immunized mice compared with normal mice. The maximum survival time was with adjuvant 84/246 even at week 24. The findings thus show that the optimum dose of CF is 5 ptg and the adjuvant of choice is 84/246.
INTRODUCTION
A cytokine called cytotoxic factor (CF) is produced during dengue virus infection of mice by T cells of the spleen, which is responsible for producing various pathological lesions that are seen in human dengue infection [1] [2] [3] [4] [5] [6] [7] [8] . Thus [16] . Control mice were similarly treated with adjuvant alone or mixed with NF. At different intervals blood was collected from the eyes of mice, sera were separated and stored at -20'C.
Assay of capillary permeability Measurement of leakage of plasma protein-bound Evans blue dye from the vascular compartment into the peritoneal cavity of the mouse was used to estimate the integrity of capillary permeability as described previously [5] . Briefly, mice were inoculated intravenously with 1 00,1l of Evans blue dye solution, followed 5 min later with CF intraperitoneally. After 30 min mice were anaesthetized and the peritoneal cavity was washed with 5 ml saline. The lavage fluid was collected and filtered through glass wool column and made up to final volume 10 ml. Optical density at 590 nm was determined with a spectrophotometer. (Fig. 3) .
In another set of experiments the dose response of CF challenge was investigated in mice immunized by CF mixed with TT or FIA or 84 246. For this, mice were taken at week 4 after immunization. Groups of immunized and control mice were challenged with various doses of CF and per cent protection was calculated. The data presented in Fig. 4 show that the capacity of immunized mice to resist the CF-induced increase in capillary permeability declined in a dose-dependent manner with all the three adjuvants, but the decline was least with 84
246.
An days with 100 and 10 LD50 of DV, respectively (Fig. 6a) . At week 4 after immunization the mean survival time was [15] [16] days (P =< 0 001) with 10 LD50 and 12-16 4 days (P > 0-05 to < 0-001) with 100 LD50 of the virus in different groups of mice. At 24 weeks after immunization the mean survival time was prolonged only in mice given 84/246 adjuvant, being 19 ± 1 5 days with 10 LD50 and 16± 0-8 days with 100 LD50 of DV (Fig. 6a,b) . The immunized mice did not develop the milder signs of illness; they developed paralysis and died within 24 h. [20] . The protection observed at week 4 was above 90% by using TT or 84/246 as adjuvant, whereas with BCG and aihydrogel it was 67 ± 4% and 33 ± 12%, respectively. At week 24 protection continued to be higher (72 + 6%) only with adjuvant 84/246. Challenge of immunized mice with DV showed significantly prolonged mean survival time, absence of signs of illness like arching of the back and ruffling of the fur, and delayed onset of parafysis compared with normal mice.
DISCUSSION
Peak response was obtained with adjuvant 84/246, which increased the mean survival time to [16] [17] [18] [19] days in different groups of mice. These findings support our earlier observations [10] . Interferon-gamma (IFN--y) selectively augments the production of IgG2a antibodies in mice [21] . The depot type adjuvants (FIA, Freund's complete adjuvant (FCA) and alhydrogel) and MDP are effective in promoting the immune response to bovine serum albumin (BSA) [19] . The immunostimulant activity of 84/246 is comparable to that of MDP [16] . Immunoadjuvants are a class of compounds with a large variety of conformations and act via different pathways. Their biological properties depend upon their capacity to activate selectively Thl or Th2 cells that control the major features of specific immune response [22] . It has been shown that FCA activate Thl cells and alhydrogel Th2 cells of mice, but it may also be relevant to humans [23] . The basis of adjuvanticity of microbial components could be their recognition by phylogenetically ancient receptors present on accessory cells. This recognition induces them to produce cytokines which selectively stimulate Thl or Th2 cells [24] .
A question that needs to be addressed is whether such a vaccine could ever find practical use, because it is based on immunization against a self protein. Presence of autoantibodies to a number of cytokines has been described and their role discussed. Anti-cytokine autoantibodies are known to block the activity of the cytokines, and are found in the serum for IL-la, IL-2, IL-4, IL-6, IL-8, IL-10, tumour necrosis factoralpha (TNF-a) and IFN-a. Small complexes between such antibodies and cytokines do not activate complement if IgG4 antibodies are involved, and do not precipitate in vivo, but are active as inflammatory complexes [25] . Bendtzen et al. [26] have proposed that a major role of anti-cyctokine autoantibodies is to facilitate, rather than neutralize, functions of cytokines in the body by acting as specific physiological carriers and regulators of cytokines. For effective immunization it is essential that such epitopes of cytokines are used which generate neutralizing antibody only.
Ideally an adjuvant should induce both high antibody levels and strong cell-mediated immunity and should be safe and comfortable. FCA is unacceptable for human use, while FIA is no longer used, although there is no evidence that it produces any adverse effects. Alum remains an important adjuvant for administration with preventive vaccines and has recently been used with synthetic malaria vaccine. In some of the clinical trials cytokines like interferons and IL-2 have been tried as adjuvant. CF is an unique cytokine induced by DV which is responsible for the production of most of the pathological lesions which could be prevented by active immunization [10] . The effect of the vaccine could be enhanced by using booster doses and appropriate adjuvants. The effect of booster doses remains to be investigated.
